Recurrence Biomarkers of Triple Negative Breast Cancer Treated with Neoadjuvant Chemotherapy and Anti-EGFR Antibodies

To find metastatic recurrence biomarkers of TNBC treated by neoadjuvant chemotherapy and anti-EGFR antibodies, investigators evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nanostring technology, and TIL assessment on H&E.